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Methods

Introduction
•
•

•

•

For the treatment of alcohol withdrawal syndrome (AWS), phenobarbital
works differently than benzodiazepines
Benzodiazepines activate only gamma-aminobutyric acid (GABA) whereas
phenobarbital has the additional mechanism of inhibiting glutamate
receptors. In the absence of alcohol, GABA receptor numbers are increased,
and glutamate receptors are decreased causing withdrawal symptoms. By
giving phenobarbital, we are counteracting both receptors
This mechanism is associated with less agitation and delirium then what is
typically seen with benzodiazepine treatment 1-3

•

•

•
•

Background/Significance
•

•

•

Figure 1. CIWA-Ar Score improvement seen within 24 hours of medication administration.

Results
•

A literature reviewed demonstrated no studies have compared the impact of
these two treatment protocols – Dexmedetomidine and Benzodiazepine vs.
Phenobarbital and Benzodiazepine – for AWS; therefore, this study seeks to
compare the two treatment protocols
Precedex (Dexmedetomidine HCL), a Central alpha-2 Adrenergic Agonist, is
utilized in the ICU as an adjunctive treatment to the standard of care –
benzodiazepines – and is based on CIWA score 1-3
Literature demonstrates Phenobarbital has been used in conjunction with
benzodiazepines based on the CIWA scale 1-3

•

•

Problem Statement
Anticipated that administration of phenobarbital treatment for management
of alcohol withdrawal reduces CIWA-Ar scores and improves CAM-ICU Scores
when compared to the administration of dexmedetomidine

Dexmedetomidine lowered CIWA scores (9.1 points), which is more than
phenobarbital does (5.7 points) within 24 hours of medication administration. (pvalue of 0.067; See Figure 1).
Length of Stay for dexmedetomidine cases were in hospital for about 11 days,
whereas the phenobarbital cases only had a mean stay of about 9 days (p=0.241;
See Figure 2).

Conclusion
•

•

Electronic health records were reviewed from this retrospective study for a goal
of 50 (up to 100) cases per group [total of 100 (up to 200)] for Henry Ford
Allegiance Health (HFAH) patients 18 years of age or older who were treated for
alcohol withdrawal syndrome between September 1st, 2017 and January 1st,
2020
Primary measures include assessing outcomes for patients given the following
alcohol withdrawal protocols:
– Phenobarbital and Benzodiazepine
– Dexmedetomidine and Benzodiazepine
Assessed and compared each treatment protocol (Phenobarbital and
Dexmedetomidine) for the following variables: number of patients, average
change in CIWA-Ar scores, average change in CAM-ICU scores, and average
change in RASS scores
Average LOS per patient in each treatment group (Phenobarbital and
Dexmedetomidine) was assessed and compared
Looked at changes in outcome variables and differences in length of stay

This study will help identify best practices for the treatment of AWS and may be of
benefit to other physicians and their patients
This study adds to the literature for administration of phenobarbital versus
dexmedetomidine for AWS management
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